THE PIPELINE PAPERS Issue No. 2

Dear Reader, The season has delivered three revelations most extraordinary – minds expanding, and modalities multiplying, quite the stir.

This month, dear reader, the industry has been positively brimming with intrigue. This author is always watching for new technologies and modalities. Because, as you know, those need careful eyes on the economic and ecological benefits. Do you not agree?

🍄 Watch No. 1: PSYCHEDELICS: TIME TO RETHINK WHAT WE STOPPED THINKING ABOUT?

“Is psychedelic medicine the future? Dear reader, it rather appears the FDA thinks so.”

This author was fascinated by the modality from a manufacturing perspective. Unlike biologics, synthetic psilocybin is a small molecule—but its ecological origins (mushrooms, cacti, African shrubs) raise legitimate sustainability questions about its supply chain at scale. Biocatalysis has been proposed as a greener alternative to natural extraction: biosynthetic routes using engineered organisms could reduce the ecological burden significantly (Science Advances, 2026). As this field scales from clinical curiosity to commercial reality, the technoeconomic and lifecycle questions will need to be answered. BioSolve Process, anyone?

Context to this: Just days after President Trump signed an executive order to accelerate access to mental health treatments, the FDA announced Commissioner’s National Priority Vouchers (CNPVs) for three companies advancing psychedelic therapies: Compass Pathways (psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD). The vouchers grant improved FDA communication and accelerated 1–2 month reviews post-filing — a considerable regulatory gift (Fierce Biotech, April 2026).

✒️ Watch No. 2: WUXI APPTEC: SPEED, COMPLEXITY & THE INTEGRATED CRDMO

“The era of the transactional outsourcing partner is, apparently, quite over.”

The author noted this with great curiosity. What strikes us is the sustainability dimension lurking within the speed story. Biocatalysis, continuous manufacturing, and flow chemistry — all prominently cited by WuXi — are also among the most process-mass-intensity-friendly approaches available. The industry’s drive toward complex modalities may, rather elegantly, align with greener manufacturing practices. The question is whether companies are measuring PMI and CO₂e alongside speed and yield — or still treating sustainability as a post-optimisation footnote.

Context to this: WuXi AppTec’s Senior VP Yu Lu made the case emphatically in a Fierce Biotech interview: pharmaceutical companies no longer merely outsource — they seek strategic partners who contribute scientific insight, operate under a single global quality system, and deliver at speed. The platform’s integrated CRDMO model connects discovery, development, and manufacturing across regions, reducing operational handoffs and compressing timelines dramatically (Fierce Biotech / WuXi AppTec, 2026).

The modalities in focus are telling: peptides, oligonucleotides, targeted protein degraders, and complex conjugates. WuXi’s capabilities span solid-phase and liquid-phase peptide synthesis, flow chemistry, biocatalysis, continuous flow chromatography, thin film evaporation, and lipid nanoparticle delivery — a formidable toolkit. In one case study, a divalent-siRNA-GalNAc conjugate IND filing was delivered in just 8 months, with crude purity increased by over 85% and final yield by over 90%.

☢️ Watch No. 3: REGENERON & TELIX: THE RADIOPHARMA MOMENT HAS ARRIVED

The author thinks that the radiopharmaceuticals are precision by design, targeted delivery minimises off-target exposure, but from a manufacturing sustainability standpoint, the sector carries a notable footprint. Medical cyclotrons are energy-intensive; radioactive waste disposal is tightly regulated and costly; and the short half-lives of many isotopes demand local or near-patient production networks with significant cold-chain implications (Open Medscience, 2026; British Journal of Radiology, 2025). As radiopharma scales from niche to mainstream, lifecycle and technoeconomic assessments will be essential — exactly the kind of analysis BioSolve Process is built to support.

Context to this: Regeneron has entered the targeted radiopharmaceutical space via a strategic collaboration with Australia’s Telix Pharmaceuticals — paying $40 million upfront to advance four solid tumour programs. The deal leverages Regeneron’s antibody portfolio with Telix’s radiopharma manufacturing platform. Should Telix opt out of the cost-sharing model, it could receive up to $2.1 billion in biobucks across the four programs (Fierce Biotech, April 2026).

Regeneron’s oncology head noted that these radiopharma drugs could be paired with blockbuster PD-1 inhibitor Libtayo, targeting lung cancer among other indications. Telix itself has been quietly building a formidable manufacturing network: acquiring Texas-based CDMO IsoTherapeutics, purchasing ARTMS and its cyclotron-based isotope production platform, and acquiring RLS Radiopharmacies and its 31-site U.S. network. The infrastructure is firmly in place.

📖 Author’s Final Thoughts

And here lies the deliciously practical bit: when new modalities arrive dressed as scientific destiny, someone still has to ask what they cost to make.

Buckland et al.8 note that BioSolve Process was used in Section 4, Table 3 to evaluate different mRNA manufacturing options by comparing cost of goods across process scenarios, giving teams an early read on which configurations may be elegant in theory but financially exhausting in practice.

That is rather the point, is it not?

BioSolve Process is built for precisely this sort of pre-implementation techno-economic scrutiny — modelling process options in silico, identifying cost drivers, and testing fit across modalities including mRNA before anyone commits the budget to stainless steel, single-use plastic, or a very expensive regret.

The output, in plain English, is not merely a number but a decision lens: a side-by-side view of manufacturing cost of goods for competing mRNA process designs, showing where materials, consumables, labour, scale, and facility choices begin to separate the sensible from the seductive.

In other words, before a new modality starts behaving like royalty, BioSolve Process asks whether it can also behave like a business.

Key References

1. Fierce Biotech. Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push. April 24, 2026. https://www.fiercebiotech.com/biotech/compass-usona-score-fda-national-priority-vouchers-amid-trump-administrations-psychedelic

2. Fierce Biotech / WuXi AppTec. How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients. 2026. https://www.fiercebiotech.com/sponsored/how-wuxi-apptecs-integrated-platform-helping-therapies-move-faster-discovery-patients

3. Fierce Biotech. Regeneron rides into radiopharma via $2.1B biobucks pact with Australia’s Telix. April 13, 2026. https://www.fiercebiotech.com/biotech/regeneron-rides-radiopharma-21b-biobucks-pact-australias-telix

4. Science Advances. Complete biosynthesis of psychedelic tryptamines from three enzymes. March 31, 2026. https://www.science.org/doi/10.1126/sciadv.aeb3034

5. Open Medscience. Ensuring Environmental Compliance and Control in Radiopharmaceutical Production. February 2026. https://openmedscience.com/ensuring-environmental-compliance-and-control-in-radiopharmaceutical-production/

6. British Journal of Radiology. Beyond green: sustainability in nuclear medicine practice. September 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12810880/

7. Biopharm Services. Events — CPhI Japan 2026. April 23, 2026. https://biopharmservices.com/events/

8. Buckland B, Sanyal G, Ranheim T, et al. Vaccine process technology—A decade of progress. Biotechnology & Bioengineering. 2024. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bit.28703

9. Biopharm Services. BioSolve Process. https://biopharmservices.com/biosolve-software/biosolve-process/

Sources verified from publicly available industry news, trade publications, and company communications as of April 2026.

Some content is generated with the help of AI.

Until next season, dear reader — may your pipelines be plentiful, your modalities multiply, and your carbon footprint remain decidedly slim.

XOXO, The Pipeline Papers